Is HRT safe? What the latest research really says

For more than two decades, women have been told that hormone replacement therapy is dangerous. That message originated with the early 2002 reporting from the Women's Health Initiative (WHI) — and it was, in retrospect, dramatically oversimplified. The current scientific consensus is very different from what most women heard a generation ago.

What the WHI actually found

The WHI studied a specific population — women on average 63 years old, more than a decade past menopause, taking conjugated equine estrogens with medroxyprogesterone acetate. The headline finding of increased breast cancer risk was real but small in absolute terms, and the risk profile changed dramatically when researchers re-analyzed by age. Women who started hormone therapy under age 60 or within ten years of menopause showed a different risk-benefit picture entirely.

The current consensus

The 2022 North American Menopause Society Position Statement is the most authoritative current guidance. It concludes that for healthy women under 60 or within ten years of menopause onset, the benefits of hormone therapy generally outweigh the risks for the treatment of bothersome vasomotor symptoms and the prevention of bone loss. ACOG's clinical practice guidance reaches the same conclusion.

Who should not use HRT

• Women with a personal history of breast cancer
• Women with active liver disease
• Women with unexplained vaginal bleeding
• Women with a history of estrogen-sensitive cancers
• Women with a recent history of blood clots, stroke, or heart attack

How modern HRT differs from the WHI protocols

Today's most commonly prescribed regimens use transdermal estradiol (a patch, gel, or cream) paired with micronized progesterone — a very different molecular and delivery profile than the oral conjugated estrogens used in the WHI. Transdermal estradiol bypasses the liver, which is associated with a lower risk of blood clots compared with oral estrogen, particularly in women with elevated baseline risk.

How Kindr evaluates safety

Every woman who starts HRT through Kindr is evaluated by a board-certified clinician who reviews her full personal and family medical history before prescribing. Risk is assessed individually — not applied as a blanket rule. If hormone therapy is not appropriate for you, your provider will say so and discuss alternatives.

Medically reviewed by Dr. Ana Lisa Carr, MD, MBA
Board-Certified Family Medicine Physician · Lead Provider / Medical Reviewer
NPI 1689841744 · Last reviewed: May 10, 2026